ArticleBiomedical engineering online2025
The influencing factors of chronic obstructive pulmonary disease concomitant with pulmonary heart disease and the diagnostic value of myocardial markers.
Article in Biomedical engineering online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo analyze the influencing factors of chronic obstructive pulmonary disease (COPD) concomitant with pulmonary heart disease (PHD) and the diagnostic value of myocardial markers.
methodsA retrospective study was conducted on 117 COPD patients. According to whether there were concomitant PHD, 117 cases were distinguished as the combined group (45 cases) and uncombined group (72 cases). Independent risk factors were screened using multivariate logistic regression analysis. The levels of serum markers were determined. Pearson correlation analysis was used to evaluate the correlation between myocardial markers and cardiac function indicators. The expression of myocardial markers in different COPD severity groups was analyzed. The receiver operating characteristic curve (ROC) was adopted to evaluate the diagnostic value of serum markers.
resultsCompared with the uncombined group, patients in the combined group had significantly increased left atrial diameter (LAD), pulmonary artery pressure (PAP), and inducible co-stimulator ligand (ICOSL) levels, with decreased left ventricular ejection fraction (LVEF) levels (P < 0.05). Serum N-terminal pro-B type natriuretic peptide (NT-proBNP), creatine kinase myocardial band (CK-MB), and cardiac troponin I (cTnI) levels were also markedly increased (P < 0.05). CTnI, CK-MB, and NT proBNP were all negatively correlated with LVEF (r = - 0.642, - 0.587, - 0.723, respectively, P < 0.001), and positively correlated with PAP (r = 0.698, 0.634, 0.781, respectively, P < 0.001). In patients with GOLD grades 3-4 even without concomitant PHD, the levels of cTnI, CK-MB, and NT proBNP were significantly higher than those in patients with GOLD grades 1-2 (P < 0.05). The area under the curve (AUC) of combined serum markers for predicting PHD in COPD patients was 0.921, with specificity and sensitivity of 88.89% and 86.11%, respectively.
conclusionsPAP, ICOSL, cTnI, CK-MB, and NT proBNP were all independent risk factors relating to the occurrence of COPD concomitant with PHD. The combined detection of cTnI, CK-MB, and NT-proBNP had certain diagnostic reference value for COPD concomitant with PHD. Monitoring these myocardial markers may provide clues for early identification of patients with COPD concomitant with PHD and assist in the clinical development of targeted intervention programs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.